Sermorelin is one of the most discussed peptides in wellness medicine, and one of the most misunderstood. It is not growth hormone. It does not introduce growth hormone into the body. What it does, in a single sentence, is signal the pituitary gland to release the growth hormone that the body already makes. Whether that distinction matters depends on what you're trying to accomplish and what the evidence actually shows.
This is a primer on what sermorelin is, where the evidence is strongest, what the legitimate uses look like, and where the marketing has gotten ahead of the science.
What it is
Sermorelin is a 29-amino-acid peptide that corresponds to the first 29 amino acids of human growth hormone-releasing hormone (GHRH). The full endogenous GHRH is 44 amino acids, but the first 29 contain essentially all of the biological activity. So sermorelin behaves like GHRH for all practical purposes.
It was originally approved by the FDA in 1990 under the brand name Geref for diagnostic testing of growth hormone deficiency in pediatric patients. The branded commercial product was discontinued years ago for business reasons, not for safety or efficacy concerns. Today, sermorelin in the United States is available only as a compounded preparation from state-licensed 503A pharmacies. It is a legal medication when prescribed by a licensed clinician and dispensed by a compliant pharmacy.
How it works
Sermorelin binds to the GHRH receptor on somatotroph cells in the anterior pituitary gland. Receptor activation triggers a signaling cascade that causes the pituitary to release its own stored growth hormone. The released hormone then circulates, binds GH receptors in peripheral tissues, and triggers the production of insulin-like growth factor 1 (IGF-1) in the liver and elsewhere. IGF-1 is the molecule that mediates most of the downstream effects of growth hormone.
The half-life of sermorelin in circulation is short, roughly 12 minutes. This is not a bug; it's the design point. A short-acting GHRH analog produces a brief pulse of pituitary signaling, which produces a brief pulse of growth hormone release, which mimics the physiologic pulsatile pattern of GH secretion that the body uses naturally. Continuous exposure to GHRH signaling would actually downregulate the receptor over time and produce diminishing returns.
Why people compare it to growth hormone
Recombinant human growth hormone (rHGH) and sermorelin are sometimes discussed as alternatives for the same indications. They are not equivalent. The distinctions matter clinically.
rHGH introduces growth hormone directly into circulation. The pituitary's own production is bypassed; in fact, the body's negative feedback loops typically suppress endogenous GH release when exogenous GH is present. rHGH produces sustained, non-pulsatile elevations in serum GH. It is more powerful, more predictable, and more associated with the side effects of supraphysiologic GH exposure: fluid retention, joint pain, carpal tunnel symptoms, insulin resistance, and over the long term, potential growth-promoting effects on tissues that should not be growing.
Sermorelin works upstream. By signaling the pituitary rather than supplying the hormone, it preserves the body's natural pulsatile release pattern and leaves negative feedback intact. If pituitary reserve is depleted (as in true adult growth hormone deficiency), sermorelin produces less response. If pituitary reserve is preserved (the typical wellness-medicine patient), it produces a meaningful GH pulse without the supraphysiologic peaks of direct rHGH dosing.
The practical implication: sermorelin is less potent than rHGH. Patients who need GH replacement for documented deficiency may not get an adequate response from a secretagogue. Patients who are functionally normal but interested in optimization tend to tolerate sermorelin well and avoid most of the issues that arise with rHGH.
What the evidence supports
The strongest data on sermorelin is in pediatric growth hormone deficiency, where the original FDA approval lies. In adults, the evidence is thinner and less robust than the marketing would suggest. A 2025 review in Translational Andrology and Urology on growth hormone secretagogues in hypogonadal males described sermorelin as a "potent GH and IGF-1 stimulator" with a favorable safety profile, but called for larger longitudinal studies before strong claims could be made. The studies that do exist tend to be small, short, and heterogeneous in design.
What can be said with reasonable confidence:
- Sermorelin produces real, measurable increases in serum GH and IGF-1 in adult patients with intact pituitary function. This is mechanistically established and reproducible in lab studies.
- The side-effect profile is favorable. Injection site reactions, occasional facial flushing, and vivid dreams are the most commonly reported. Serious adverse events are rare.
- Sleep quality improves in many patients. Growth hormone is naturally released in the largest pulse during stage 3 (slow-wave) sleep, and patients commonly report deeper sleep within the first few weeks of nightly sermorelin therapy.
- Body composition shifts are modest but real. Slight reductions in fat mass and slight increases in lean mass have been documented in small studies, though the magnitude is far smaller than what's achievable with diet and resistance training alone.
What's less well established:
- Antiaging benefit. The claim that sermorelin slows aging is widely marketed and poorly supported. GH and IGF-1 are involved in tissue maintenance, and lower GH levels with age are real, but whether restoring those levels translates to longer healthspan or lifespan has not been demonstrated in long-term human trials.
- Cognitive improvement. Some patients report better cognitive function on sermorelin. This may reflect better sleep, real GH/IGF-1 effects, or placebo. Robust trials in cognitively normal adults are scarce.
- Athletic performance enhancement. Sermorelin is on the World Anti-Doping Agency prohibited list and is not legal for use in competitive sport. The performance enhancement claims have not been validated in controlled studies.
How it's typically used
The standard adult protocol is a subcutaneous injection at bedtime, five to seven nights per week, of 200 to 300 micrograms. The bedtime timing is intentional: it aligns the induced GH pulse with the natural peak of GH secretion during slow-wave sleep, when receptor sensitivity is highest. Injections during daytime produce a smaller relative effect.
Some protocols combine sermorelin with ipamorelin or a similar growth hormone-releasing peptide (GHRP). The combination is synergistic at the receptor level: GHRH and GHRP target two different pathways in the pituitary, and combining them produces a larger GH pulse than either one alone. A 2025 review reported a 47-fold increase in pulsatile GH secretion with GHRP-2 alone, 20-fold with GHRH-class peptides alone, and 54-fold with both combined. Whether the synergistic increase translates into proportionally larger clinical benefit is less clear.
Other adjacent peptides include tesamorelin (a longer-acting GHRH analog approved by the FDA for HIV-associated lipodystrophy) and CJC-1295 with DAC (a sustained-release GHRH analog with a half-life measured in days). Each has different trade-offs in convenience, potency, and how closely it mimics physiologic pulsatility. Sermorelin is the most pulsatile, the most short-acting, and arguably the closest analog to the body's natural pattern.
Who should not use it
Sermorelin is contraindicated in patients with active malignancy, since growth hormone has growth-promoting effects on tissues. It is not appropriate during pregnancy or breastfeeding. Patients with active diabetic retinopathy should not use it, as elevated GH can worsen retinopathy. It should be used with caution in patients with diabetes, since GH antagonizes some of insulin's effects and can transiently worsen glycemic control.
A pre-treatment workup that includes IGF-1, fasting glucose, HbA1c, lipid panel, and a basic metabolic panel is reasonable. Periodic monitoring of IGF-1 (typically every 3-6 months) helps confirm that dosing is producing the expected biological effect and that levels remain within a safe range.
What sermorelin won't do
It will not, in any reasonable timeframe, transform body composition the way diet and resistance training will. The marketing that positions peptide therapy as an alternative to exercise is wrong. Sermorelin works best as an adjunct to a baseline of good sleep, adequate protein intake, and consistent strength training. Without those foundations, the effect is small.
It will not reverse aging. The biology of aging is multifactorial; growth hormone is one input among many, and there is no evidence that supplementing GH (or GH-releasing signals) in functionally normal adults extends healthspan or lifespan. There is some evidence in the other direction: lower IGF-1 levels are associated with longer life in some observational studies, which is not what the antiaging marketing would predict.
It will not produce the same effect as rHGH at therapeutic doses. Patients with diagnosed adult growth hormone deficiency should be evaluated by an endocrinologist and treated according to standard endocrine guidelines, not via wellness peptide protocols.
The compounding and regulatory picture
Sermorelin in the United States is dispensed exclusively by 503A and 503B compounding pharmacies. Quality varies. A reputable compounding pharmacy will use USP-grade active pharmaceutical ingredient, follow current Good Manufacturing Practice (cGMP) standards, run sterility and potency testing on each batch, and provide lot-level documentation on request. A patient or prescriber is within reasonable rights to ask for that documentation.
The FDA does not approve compounded sermorelin as a finished product, and federal law restricts the marketing of compounded medications. Compounded peptides cannot be marketed as "FDA-approved" because the finished compounded product is not. The active ingredient is identical to what was originally approved; the manufacturing path is different.
The Bottom Line
Sermorelin is a legitimate peptide therapy with a defined mechanism, a favorable safety profile, and a modest but real effect on GH and IGF-1 levels in adults with intact pituitary function. It is not growth hormone, it is not an antiaging breakthrough, and it is not a substitute for the basics of sleep, protein, and resistance training. Used thoughtfully under medical supervision, it can be a useful adjunct for patients interested in optimization. Used as marketed in the wellness space, it often promises more than it can deliver.
If you're considering sermorelin, work with a clinician who will run baseline labs, monitor IGF-1, and discuss the specific outcomes you're hoping for. The right framing of expectations matters more than the dose.